Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
CADTH
Record ID 32014000801
English
Authors' recommendations:
For the treatment of VMT, the manufacturer suggests that ocriplasmin is likely to have a cost per QALY of around $40,000 under assumptions of sustained clinical benefit over a 37.5-year time frame after one injection. In the CDR reanalysis (reference case) where non-health care costs were excluded and treatment costs of bilateral disease are included, the ICUR increased to $55,544 per QALY. When the uncertainty in long-term relative efficacy is explored in sensitivity analysis using the CDR reference case, the incremental cost per QALY increases from $63,000 to > $100,000.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0337_Jetrea_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Fibrinolysin
- Peptide Fragments
- Cost-Benefit Analysis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.